Keith M. Kerr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keith M. Kerr has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- Martin Reck
LungenClinic Grosshansdorf 18 Grosshansdorf
12 shared publications - Solange Peters
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
12 shared publications - David Harpole
Duke University
11 shared publications - David P. Carbone
Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute, Columbus, Ohio, United States
11 shared publications - David R. Gandara
University of California Davis Comprehensive Cancer Center, Sacramento, CA
11 shared publications - Francoise Mornex
Centre Hospitalier Lyon-Sud
11 shared publications
Latest Publications
- Open Access
- 5 January 2023
- Published by BMJ in Journal of Clinical Pathology
- Vol. 77 (2) , 135-139
Improving practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions
Aims Programmed cell death ligand 1 (PD-L1) expression, used universally to predict response of non-small cell lung cancer (NSCLC) to immune-modulating drugs, is a fragile biomarker due to biological heterogeneity and challenges in interpretation. The aim of this study was to assess current PD-L1 testing practices in the UK, which may help to define strategies to improve its reliability and consistency. Methods A questionnaire covering NSCLC PD-L1 testing practice was devised and members of the Association of Pulmonary Pathologists were invited to complete this online. Results Of 44 pathologists identified as involved in PD-L1 testing, 32 (73%) responded. There was good consistency in practice and approach, but there was wide variability in the distribution of PD-L1 scoring. Although the proportions of scores falling into the three groups (negative, low and high) defined by the 1% and 50% ‘cut-offs’ (38%, 33% and 27%, respectively) reflect the general experience, the range within each group was wide at 23–70%, 10–60% and 15–36%, respectively. Conclusions There is inconsistency in the crucial endpoint of PD-L1 testing of NSCLC, the expression score that guides management. Addressing this requires formal networking of individuals and laboratories to devise a strategy for its reduction.
- 5 January 2023
- Published by BMJ in Journal of Clinical Pathology
- Vol. 77 (2) , 135-139
Open AccessImproving practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions
Aims Programmed cell death ligand 1 (PD-L1) expression, used universally to predict response of non-small cell lung cancer (NSCLC) to immune-modulating drugs, is a fragile biomarker due to biological heterogeneity and challenges in interpretation. The aim of this study was to assess current PD-L1 testing practices in the UK, which may help to define strategies to improve its reliability and consistency. Methods A questionnaire covering NSCLC PD-L1 testing practice was devised and members of the Association of Pulmonary Pathologists were invited to complete this online. Results Of 44 pathologists identified as involved in PD-L1 testing, 32 (73%) responded. There was good consistency in practice and approach, but there was wide variability in the distribution of PD-L1 scoring. Although the proportions of scores falling into the three groups (negative, low and high) defined by the 1% and 50% ‘cut-offs’ (38%, 33% and 27%, respectively) reflect the general experience, the range within each group was wide at 23–70%, 10–60% and 15–36%, respectively. Conclusions There is inconsistency in the crucial endpoint of PD-L1 testing of NSCLC, the expression score that guides management. Addressing this requires formal networking of individuals and laboratories to devise a strategy for its reduction.
- Open Access
- 8 January 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (1) , 72
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe
Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical practice for several tumor types. However, NGS implementation, and therefore patient access, varies across Europe; a multi-stakeholder collaboration is needed to establish the conditions required to improve this discrepancy. In that regard, we set up European Alliance for Personalised Medicine (EAPM)-led expert panels during the first half of 2021, including key stakeholders from across 10 European countries covering medical, economic, patient, industry, and governmental expertise. We describe the outcomes of these panels in order to define and explore the necessary conditions for NGS implementation into routine clinical care to enable patient access, identify specific challenges in achieving them, and make short- and long-term recommendations. The main challenges identified relate to the demand for NGS tests (governance, clinical standardization, and awareness and education) and supply of tests (equitable reimbursement, infrastructure for conducting and validating tests, and testing access driven by evidence generation). Recommendations made to resolve each of these challenges should aid multi-stakeholder collaboration between national and European initiatives, to complement, support, and mutually reinforce efforts to improve patient care.
- 8 January 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (1) , 72
Open AccessIdentifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe
Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical practice for several tumor types. However, NGS implementation, and therefore patient access, varies across Europe; a multi-stakeholder collaboration is needed to establish the conditions required to improve this discrepancy. In that regard, we set up European Alliance for Personalised Medicine (EAPM)-led expert panels during the first half of 2021, including key stakeholders from across 10 European countries covering medical, economic, patient, industry, and governmental expertise. We describe the outcomes of these panels in order to define and explore the necessary conditions for NGS implementation into routine clinical care to enable patient access, identify specific challenges in achieving them, and make short- and long-term recommendations. The main challenges identified relate to the demand for NGS tests (governance, clinical standardization, and awareness and education) and supply of tests (equitable reimbursement, infrastructure for conducting and validating tests, and testing access driven by evidence generation). Recommendations made to resolve each of these challenges should aid multi-stakeholder collaboration between national and European initiatives, to complement, support, and mutually reinforce efforts to improve patient care.
- Open Access
- 1 December 2021
- Published by Elsevier in Lung Cancer
- Vol. 162, 42-53
Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges
- 1 December 2021
- Published by Elsevier in Lung Cancer
- Vol. 162, 42-53
Open AccessMolecular testing in stage I–III non-small cell lung cancer: Approaches and challenges
- Top Cited PapersOpen Access
- 1 April 2021
- Published by Elsevier in Lung Cancer
- Vol. 154, 161-175
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
- 1 April 2021
- Published by Elsevier in Lung Cancer
- Vol. 154, 161-175
Top Cited PapersOpen AccessThe evolving landscape of biomarker testing for non-small cell lung cancer in Europe
- Open Access
- 1 October 2020
- Published by Elsevier in Lung Cancer
- Vol. 148, 159-165
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
- 1 October 2020
- Published by Elsevier in Lung Cancer
- Vol. 148, 159-165
Open AccessNon-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
- Open Access
- 1 August 2020
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (8) , 1306-1316
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
- 1 August 2020
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 15 (8) , 1306-1316
Open AccessProgrammed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
- Open Access
- 1 March 2020
- Published by Elsevier in Lung Cancer
- Vol. 141, 101-106
Cytology for PD-L1 testing: A systematic review
- 1 March 2020
- Published by Elsevier in Lung Cancer
- Vol. 141, 101-106
Open AccessCytology for PD-L1 testing: A systematic review
- 17 March 2018
- Published by Springer Nature
- p. 192-194
Granular Cell Tumor
- 17 March 2018
- Published by Springer Nature
- p. 191-192
Glandular Papilloma, Lung